Modotuximab
Modotuximab
Modotuximab (pronunciation: mo-do-tux-i-mab) is a monoclonal antibody designed for the treatment of certain types of cancer. It is a type of immunotherapy that uses the body's immune system to help fight cancer.
Etymology
The name "Modotuximab" is derived from the words "monoclonal", "do" (from the Greek word "dothien" meaning "to give"), and "tuximab" (a common suffix for monoclonal antibodies).
Mechanism of Action
Modotuximab works by binding to a specific protein found on the surface of cancer cells. This binding triggers the body's immune system to attack and destroy the cancer cells. The specific protein that Modotuximab targets is called CD20, which is commonly found on B cells, a type of white blood cell that can become cancerous.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
- CD20: A protein found on the surface of B cells.
- B cells: A type of white blood cell that makes antibodies.
See Also
External links
- Medical encyclopedia article on Modotuximab
- Wikipedia's article - Modotuximab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski